Influenza caused by influenza viruses is a global health threat. Existing inactivated and attenuated vaccines provide a certain degree of protection, while their protection is limited, requiring regular booster vaccinations. Moreover, these vaccines are not effective against new viral strains. To overcome these limitations, researchers are developing new influenza vaccines that can provide effective broad-spectrum protection, among which the recombinant adenovirus-based oral vaccines combine the advantages of adenovirus vector technology and oral administration, showing great potential. Such oral vaccines can effectively activate mucosal immunity, produce secretory immunoglobulin A, form an efficient immune barrier, and greatly increase vaccine acceptance through the convenience of oral administration, being suitable for large-scale emergency vaccination in the context of influenza pandemics. Although adenovirus vector-based oral vaccines for influenza have shown good immunogenicity and protective effects in preclinical studies, effectively improving their stability in the gastrointestinal environment and immune protection effects remains a challenge. Future research will focus on optimizing vector vaccine antigen design, immunization strategies, etc. to improve the effectiveness and applicability of oral vaccines, providing more prevention options for public health.